{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:21:02Z","timestamp":1788283262399,"version":"build-2803163510"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>\n                    Neurocutaneous melanocytosis (NCM) is a disorder characterized by multiple or large congenital nevi and excessive proliferation of melanocytes in the leptomeninges and brain parenchyma. The majority of NCM is a result of somatic mosaicism due to a single postzygotic mutation in codon 61 of\n                    <jats:italic toggle=\"yes\">NRAS.<\/jats:italic>\n                    Patients with NCM are at high risk of developing leptomeningeal melanoma. The prognosis for leptomeningeal melanoma is poor with no known effective treatment options. We describe the clinical features, treatment, and outcome of 4 children with NCM and leptomeningeal melanoma and discuss the latest molecular findings and treatment options for this rare condition.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000001680","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T01:53:17Z","timestamp":1574646797000},"page":"e195-e197","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Neurocutaneous Melanocytosis and Leptomeningeal Melanoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Victoria","family":"Mitre","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Heym","sequence":"additional","affiliation":[{"name":"Cook Children\u2019s Medical Center, Fortworth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Clark","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Venkatramani","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"pt 1","key":"R1-20260901","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0190-9622(91)70115-I","article-title":"Neurocutaneous melanosis: definition and review of the literature","volume":"24","author":"Kadonaga","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"R2-20260901","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00381-003-0835-9","article-title":"Neurocutaneous melanosis","volume":"20","author":"Di Rocco","year":"2004","journal-title":"Childs Nerv Syst"},{"key":"R3-20260901","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/jid.2013.70","article-title":"Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS","volume":"133","author":"Kinsler","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R4-20260901","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/CMR.0000000000000188","article-title":"Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis","volume":"25","author":"Salgado","year":"2015","journal-title":"Melanoma Res"},{"key":"R5-20260901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07218.x","article-title":"Melanoma risk in congenital melanocytic naevi: a systematic review","volume":"155","author":"Krengel","year":"2006","journal-title":"Br J Dermatol"},{"key":"R6-20260901","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaad.2005.07.046","article-title":"Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry","volume":"53","author":"Agero","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R7-20260901","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1542\/peds.106.4.736","article-title":"Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis","volume":"106","author":"Bittencourt","year":"2000","journal-title":"Pediatrics"},{"key":"R8-20260901","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jaad.2008.11.022","article-title":"Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center\u2019s experience","volume":"61","author":"Lovett","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R9-20260901","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1469-8749.2012.04275.x","article-title":"Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis","volume":"54","author":"Ramaswamy","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"R10-20260901","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2350\/14-10-1566-OA.1","article-title":"BRAF mutations are also associated with neurocutaneous melanocytosis and large\/giant congenital melanocytic nevi","volume":"18","author":"Salgado","year":"2015","journal-title":"Pediatr Dev Pathol"},{"key":"R11-20260901","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pde.12400","article-title":"Case reports of fatal or metastasizing melanoma in children and adolescents: a systematic analysis of the literature","volume":"32","author":"Neuhold","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"R12-20260901","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/bjc.2017.49","article-title":"MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children","volume":"116","author":"Kinsler","year":"2017","journal-title":"Br J Cancer"},{"key":"R13-20260901","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/pbc.22279","article-title":"Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma","volume":"54","author":"Subbiah","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20260901","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2018.04.010","article-title":"MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: results of a retrospective multicentre analysis of 364 patients","volume":"98","author":"Kirchberger","year":"2018","journal-title":"Eur J Cancer"},{"key":"R15-20260901","doi-asserted-by":"crossref","first-page":"551","DOI":"10.18632\/oncotarget.26560","article-title":"Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy","volume":"10","author":"Toll","year":"2019","journal-title":"Oncotarget"},{"issue":"suppl","key":"R16-20260901","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN)","volume":"36","author":"Geoerger","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20260901","doi-asserted-by":"crossref","first-page":"239","DOI":"10.21873\/cgp.20082","article-title":"The dual PI3K\/mToR inhibitor omipalisib\/GSK2126458 inhibits clonogenic growth in oncogenically-transformed cells from neurocutaneous melanocytosis","volume":"15","author":"Basu","year":"2018","journal-title":"Cancer Genomics Proteomics"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:04:03Z","timestamp":1788282243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001680","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"2019-10-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}